US5151444B1
(en)
*
|
1987-09-18 |
1999-07-06 |
R Tech Ueno Ltd |
Ocular hypotensive agents
|
US5212200A
(en)
*
|
1987-09-18 |
1993-05-18 |
R-Tech Ueno, Ltd. |
Ocular hypotensive agents
|
US6420422B1
(en)
|
1987-09-18 |
2002-07-16 |
Sucampo Pharmaceuticals, Inc. |
Ocular hypotensive agents
|
US5236907A
(en)
*
|
1988-10-01 |
1993-08-17 |
R-Tech Ueno Ltd. |
Ocular hypotensive agents
|
US5166178B1
(en)
*
|
1987-09-18 |
1998-07-21 |
R Tech Ueno Ltd |
Ocular hypotensive agents
|
US5565492A
(en)
*
|
1988-07-18 |
1996-10-15 |
Alcon Laboratories, Inc. |
Prostaglandin combinations in glaucoma therapy
|
ATE101342T1
(de)
|
1988-09-06 |
1994-02-15 |
Kabi Pharmacia Ab |
Prostaglandinderivate zur behandlung des gruenen stars oder einer okularen hypertension.
|
US6187813B1
(en)
|
1990-04-10 |
2001-02-13 |
Pharmacia & Upjohn Aktiebolag |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
US5296504A
(en)
*
|
1988-09-06 |
1994-03-22 |
Kabi Pharmacia |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
US5321128A
(en)
*
|
1988-09-06 |
1994-06-14 |
Kabi Pharmacia Ab |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
US5194429A
(en)
*
|
1988-10-01 |
1993-03-16 |
K.K. Ueno Seiyaku Oyo Kenkyujo |
Ocular hypotensive agents
|
HU212570B
(en)
*
|
1991-06-24 |
1996-08-29 |
Chinoin Gyogyszer Es Vegyeszet |
Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
|
US5223537A
(en)
*
|
1991-07-23 |
1993-06-29 |
Kabi Pharmacia Ab |
Method and composition for treatment of gastric and duodenal disorders
|
US5972991A
(en)
|
1992-09-21 |
1999-10-26 |
Allergan |
Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
US5688819A
(en)
*
|
1992-09-21 |
1997-11-18 |
Allergan |
Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
|
US5352708A
(en)
*
|
1992-09-21 |
1994-10-04 |
Allergan, Inc. |
Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
|
US5834498A
(en)
*
|
1992-09-21 |
1998-11-10 |
Allergan |
Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
US6602900B2
(en)
*
|
1992-09-21 |
2003-08-05 |
Allergan, Inc. |
Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
US5468778A
(en)
*
|
1992-09-24 |
1995-11-21 |
Allergan, Inc. |
Method of lowering intraocular pressure by administering a pharmaceutical composition containing 7-(5-substituted cyclopentyl) and 7-(5-substituted-cyclopentenyl) 5-heptenoic acids and derivatives
|
WO1994008585A1
(en)
*
|
1992-10-13 |
1994-04-28 |
Alcon Laboratories, Inc. |
Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
|
US5332730A
(en)
*
|
1992-10-16 |
1994-07-26 |
Allergan, Inc. |
Azido derivatives of cyclopentane heptanoic or heptenoic acid
|
US5385945A
(en)
*
|
1992-10-21 |
1995-01-31 |
Allergan, Inc. |
7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) heptyl alcohols, heptylamines and heptanoic acid amides, and method of lowering intraocular pressure in the eye of a mammal by administration of these novel compounds
|
US5328933A
(en)
*
|
1992-10-28 |
1994-07-12 |
Allergan, Inc. |
Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues
|
US5312842A
(en)
*
|
1992-10-30 |
1994-05-17 |
Allergan, Inc. |
Cyclopentane heptenylsulfinylalkyl and heptanylsulfinylalkyl-2-aliphatic or aryl aliphatic derivatives
|
US5510383A
(en)
*
|
1993-08-03 |
1996-04-23 |
Alcon Laboratories, Inc. |
Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
|
US6184250B1
(en)
*
|
1993-08-03 |
2001-02-06 |
Alcon Laboratories, Inc. |
Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
|
US5387608A
(en)
*
|
1993-08-17 |
1995-02-07 |
Allergan, Inc. |
Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl sulfonamidomethyl and derivatives thereof as therapeutic agents
|
US5476872A
(en)
*
|
1993-10-18 |
1995-12-19 |
Allergan, Inc. |
1,11-diesters of prostaglandin-F2α having a polar ester group at C-1
|
US5486540A
(en)
*
|
1993-10-28 |
1996-01-23 |
Allergan, Inc. |
Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents
|
US5721273A
(en)
|
1993-12-15 |
1998-02-24 |
Alcon Laboratories, Inc. |
Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
|
US5627209A
(en)
*
|
1993-12-15 |
1997-05-06 |
Alcon Laboratories, Inc. |
Use of certain 9-haloprostaglandins to treat glaucoma and ocular hypertension
|
US5650431A
(en)
*
|
1993-12-28 |
1997-07-22 |
Allergan |
Thromboxane ligands without blood clotting side effects
|
US5741812A
(en)
*
|
1993-12-28 |
1998-04-21 |
Allergan |
Thromboxane ligands without blood clotting side effects
|
US5545665A
(en)
*
|
1993-12-28 |
1996-08-13 |
Allergan |
Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
|
US6462077B1
(en)
|
1993-12-28 |
2002-10-08 |
Allergan, Inc. |
Thromboxane ligands without blood clotting side effects
|
US5416106A
(en)
*
|
1993-12-28 |
1995-05-16 |
Allergan, Inc. |
7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxobicyclo-[3.2.1] octane and derivatives thereof
|
US5462968A
(en)
*
|
1994-01-19 |
1995-10-31 |
Allergan, Inc. |
EP2 -receptor agonists as agents for lowering intraocular pressure
|
US5516796A
(en)
*
|
1994-03-24 |
1996-05-14 |
Kabi Pharmacia Ab |
Thioprostaglandins and -prostaglandin-like compounds and therapeutic uses thereof
|
SE9401087D0
(sv)
*
|
1994-03-31 |
1994-03-31 |
Pharmacia Ab |
New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
SE9403158D0
(sv)
*
|
1994-09-21 |
1994-09-21 |
Pharmacia Ab |
New use of prostaglandins
|
US5807892A
(en)
*
|
1994-09-30 |
1998-09-15 |
Alcon Laboratories, Inc. |
Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
|
US5698733A
(en)
*
|
1994-09-30 |
1997-12-16 |
Alcon Laboratories, Inc. |
Use of 9-deoxy prostaglandin derivatives to treat glaucoma
|
US6294563B1
(en)
|
1994-10-27 |
2001-09-25 |
Allergan Sales, Inc. |
Combinations of prostaglandins and brimonidine or derivatives thereof
|
WO1996036599A1
(en)
*
|
1995-05-18 |
1996-11-21 |
Allergan |
Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension
|
WO1998021180A1
(en)
|
1995-06-07 |
1998-05-22 |
Alcon Laboratories, Inc. |
Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
|
US5698598A
(en)
*
|
1995-08-04 |
1997-12-16 |
Allergan |
EP2 -receptor agonists as agents for lowering intraocular pressure
|
WO1997023225A1
(en)
*
|
1995-12-22 |
1997-07-03 |
Alcon Laboratories, Inc. |
Combinations of dp and fp type prostaglandins for lowering iop
|
US5700835A
(en)
*
|
1995-12-22 |
1997-12-23 |
Alcon Laboratories, Inc. |
3-Oxa-D-prostaglandins for lowering IOP
|
US5658897A
(en)
*
|
1996-04-08 |
1997-08-19 |
Allergan |
Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl phosphinyloxyalkyl or phosphonamidoalkyl as therapeutic agents
|
WO1998012175A1
(fr)
*
|
1996-09-17 |
1998-03-26 |
Asahi Glass Company Ltd. |
Derives de prostaglandine fluores et medicaments
|
US6235779B1
(en)
|
1996-11-12 |
2001-05-22 |
Alcon Laboratories, Inc. |
Use of cis-Δ4 analogs of prostaglandins as ocular hypotensives
|
WO1998020880A2
(en)
*
|
1996-11-12 |
1998-05-22 |
Alcon Laboratories, Inc. |
11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
|
DE69823852T2
(de)
|
1997-02-04 |
2005-05-19 |
Johnstone, Murray A., Seattle |
Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
|
WO1998039293A2
(en)
|
1997-03-07 |
1998-09-11 |
Alcon Laboratories, Inc. |
13-thia prostaglandins for use in glaucoma therapy
|
US6770675B2
(en)
|
1997-03-17 |
2004-08-03 |
Novartis Ag |
Compositions and methods for reducing ocular hypertension
|
AU725677B2
(en)
*
|
1997-05-09 |
2000-10-19 |
Mount Sinai School Of Medicine Of The City University Of New York, The |
8-iso-prostaglandins for glaucoma therapy
|
IL134840A0
(en)
*
|
1997-09-09 |
2001-05-20 |
Procter & Gamble |
Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
|
ATE270660T1
(de)
*
|
1997-09-09 |
2004-07-15 |
Univ Duke |
Aromatische c16-c20-substituierte tetrahydro- prostaglandine verwendbar wie fp agoniste
|
WO1999018969A1
(fr)
*
|
1997-10-13 |
1999-04-22 |
R-Tech Ueno, Ltd. |
Composition curative de l'hypertension intraoculaire ou du glaucome
|
WO1999018970A1
(fr)
*
|
1997-10-14 |
1999-04-22 |
Senju Pharmaceutical Co., Ltd. |
Medicaments a action preventive et remedes contre les troubles circulatoires ophtalmiques
|
US6646001B2
(en)
|
1997-12-19 |
2003-11-11 |
Alcon Manufacturing, Ltd. |
Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
|
US6066671A
(en)
|
1997-12-19 |
2000-05-23 |
Alcon Laboratories, Inc. |
Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
|
US6492417B1
(en)
|
1997-12-22 |
2002-12-10 |
Alcon Manufacturing, Ltd. |
11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
|
US6441033B1
(en)
|
1997-12-22 |
2002-08-27 |
Alcon Manufacturing, Ltd. |
11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists
|
ES2223180T3
(es)
|
1998-03-31 |
2005-02-16 |
Duke University |
Prostaglandinas c11 oximetil e hidroxilamino utilizadas como medicamentos.
|
US6225348B1
(en)
|
1998-08-20 |
2001-05-01 |
Alfred W. Paulsen |
Method of treating macular degeneration with a prostaglandin derivative
|
US6160013A
(en)
*
|
1998-12-17 |
2000-12-12 |
Alcon Laboratories, Inc. |
14-aza prostaglandins for the treatment of glaucoma and ocular hypertension
|
SE9900672D0
(sv)
*
|
1999-02-25 |
1999-02-25 |
Synphora Ab |
Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
|
EP1159266B1
(de)
|
1999-03-05 |
2004-11-03 |
Duke University |
C-16 ungesätigte fp-selektive prostaglandin analoge
|
US6894175B1
(en)
*
|
1999-08-04 |
2005-05-17 |
The Procter & Gamble Company |
2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
|
TWI290470B
(en)
|
1999-12-01 |
2007-12-01 |
Sankyo Co |
The composition for treating glaucoma
|
AU4114301A
(en)
*
|
2000-03-16 |
2001-09-24 |
Sucampo Ag |
Treatment of ocular hypertension and glaucoma
|
US6458836B1
(en)
|
2000-03-16 |
2002-10-01 |
Sucampo, A.G. |
Treatment of ocular hypertension and glaucoma
|
US6956036B1
(en)
|
2000-03-17 |
2005-10-18 |
Alcon, Inc. |
6-hydroxy-indazole derivatives for treating glaucoma
|
US6927233B1
(en)
|
2000-03-17 |
2005-08-09 |
Alcon, Inc. |
5ht2 agonists for controlling IOP and treating glaucoma
|
US6806285B1
(en)
|
2000-03-17 |
2004-10-19 |
Alcon, Inc. |
5-Hydroxyl indole derivatives for treating glaucoma
|
US7012090B1
(en)
|
2000-03-17 |
2006-03-14 |
Alcon, Inc. |
Pyranoindoles for treating glaucoma
|
US6660870B1
(en)
|
2000-03-17 |
2003-12-09 |
Alcon, Inc. |
2-acylaminobenzimidazole derivatives for treating glaucoma
|
US7005443B1
(en)
|
2000-03-17 |
2006-02-28 |
Alcon, Inc. |
5-Hydroxy indazole derivatives for treating glaucoma
|
US20030119846A1
(en)
*
|
2000-03-17 |
2003-06-26 |
Collier Jr Robert J. |
Compounds with 5-ht activity useful for controlling visual field loss
|
US20020013294A1
(en)
*
|
2000-03-31 |
2002-01-31 |
Delong Mitchell Anthony |
Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
|
US20020172693A1
(en)
*
|
2000-03-31 |
2002-11-21 |
Delong Michell Anthony |
Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
|
US20020037914A1
(en)
*
|
2000-03-31 |
2002-03-28 |
Delong Mitchell Anthony |
Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
|
US20020146439A1
(en)
*
|
2000-03-31 |
2002-10-10 |
Delong Mitchell Anthony |
Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
|
AU2001261019A1
(en)
*
|
2000-05-15 |
2001-11-26 |
Pharmacia And Upjohn Company |
Process and intermediates to prepare latanoprost
|
GB0012249D0
(en)
*
|
2000-05-19 |
2000-07-12 |
Chirotech Technology Ltd |
Process for the preparation of 11-oxaprostaglandins
|
US6726918B1
(en)
|
2000-07-05 |
2004-04-27 |
Oculex Pharmaceuticals, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
PE20020146A1
(es)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
US20020035148A1
(en)
*
|
2000-07-20 |
2002-03-21 |
Ryuji Ueno |
Treatment of ocular hypertension
|
US6586462B2
(en)
|
2000-10-20 |
2003-07-01 |
Allergan, Inc. |
ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
|
US6376533B1
(en)
*
|
2000-10-20 |
2002-04-23 |
Allergan Sales, Inc. |
Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
|
WO2004098807A1
(en)
*
|
2000-11-21 |
2004-11-18 |
Barsplice Products, Inc. |
Method of making steel couplers for joining concrete reinforcing bars
|
AU3649502A
(en)
|
2000-11-29 |
2002-06-11 |
Oculex Pharm Inc |
Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
|
WO2002085248A2
(en)
*
|
2001-04-23 |
2002-10-31 |
Board Of Regents The University Of Texas System |
Prostanoids augment ocular drug penetration
|
KR100437873B1
(ko)
|
2001-05-08 |
2004-06-26 |
연성정밀화학(주) |
프로스타글란딘 유도체의 제조방법 및 그의 입체특이적출발물질
|
US20030212107A1
(en)
*
|
2001-05-10 |
2003-11-13 |
Kapin Michael A. |
R-reliprodil for treating glaucoma
|
GB0112699D0
(en)
*
|
2001-05-24 |
2001-07-18 |
Resolution Chemicals Ltd |
Process for the preparation of prostglandins and analogues thereof
|
TWI298257B
(en)
|
2001-05-31 |
2008-07-01 |
Allergan Inc |
Hypotensive lipid and timolol compositions and methods of using same
|
MXPA03010806A
(es)
*
|
2001-06-01 |
2004-11-22 |
Alcon Inc |
Nuevos analogos de arilaminopropano y su uso para el tratamiento de glaucoma.
|
BR0210241A
(pt)
*
|
2001-06-01 |
2004-08-10 |
Alcon Inc |
Piranoindazóis e seu uso no tratamento de glaucoma
|
CA2447156A1
(en)
*
|
2001-06-01 |
2002-12-12 |
Alcon, Inc. |
Novel fused indazoles and indoles and their use for the treatment of glaucoma
|
US20050222094A1
(en)
*
|
2001-06-14 |
2005-10-06 |
Burk Robert M |
Treatment of inflammatory bowel disease
|
US7872045B2
(en)
*
|
2001-06-14 |
2011-01-18 |
Allergan, Inc. |
Combination therapy for glaucoma treatment
|
US20030027853A1
(en)
*
|
2001-06-14 |
2003-02-06 |
Allergan Sales, Inc. |
3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
|
US6713268B2
(en)
*
|
2001-06-26 |
2004-03-30 |
Allergan, Inc. |
Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
|
EP1406854A1
(de)
|
2001-07-17 |
2004-04-14 |
PHARMACIA & UPJOHN COMPANY |
Verfahren und zwischenprodukten zur herstellung von latanoprost
|
US20030187071A1
(en)
*
|
2001-07-17 |
2003-10-02 |
Henegar Kevin E. |
Process and intermediates to prepare latanoprost
|
EP1420793A1
(de)
*
|
2001-08-23 |
2004-05-26 |
Sucampo AG |
Methode und zusammenstellung zur behandlung von erhöhtem augenbinnendruck und glaukom
|
US6884816B2
(en)
*
|
2001-08-31 |
2005-04-26 |
Alcon, Inc. |
Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
|
US20040254230A1
(en)
*
|
2001-12-03 |
2004-12-16 |
Ogidigben Miller J. |
Method for treating ocular hypertension
|
TW200305424A
(en)
|
2002-01-29 |
2003-11-01 |
Santen Pharmaceutical Co Ltd |
Glaucoma-treating agent comprising bunazosin and prostaglandin
|
US7351404B2
(en)
*
|
2002-02-04 |
2008-04-01 |
Allergan, Inc. |
Method of enhancing hair growth
|
US8758733B2
(en)
|
2002-02-04 |
2014-06-24 |
Allergan, Inc. |
Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
|
US9216183B2
(en)
|
2002-02-04 |
2015-12-22 |
Allergan, Inc. |
Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
|
US20040110776A1
(en)
*
|
2002-02-22 |
2004-06-10 |
Iok-Hou Pang |
Use of propentofylline to control intraocular pressure
|
CA2487977A1
(en)
*
|
2002-06-06 |
2003-12-18 |
Merck Frosst Canada & Co./Merck Frosst Canada & Cie |
1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
|
EP1513589B1
(de)
|
2002-06-06 |
2010-11-10 |
Merck Frosst Canada Ltd. |
1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
|
US6864282B2
(en)
|
2002-08-05 |
2005-03-08 |
Allergan, Inc. |
9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
|
US8580851B2
(en)
|
2002-08-21 |
2013-11-12 |
Sucampo Ag |
Ophthalmic solution
|
US20040076678A1
(en)
*
|
2002-08-21 |
2004-04-22 |
Sucampo Ag |
Opthalmic solution
|
EP1545517A1
(de)
*
|
2002-08-28 |
2005-06-29 |
Merck Frosst Canada & Co. |
Oxazolidin-2-on und thiazolidin-2-on-derivate zur verwendung als ep4-rezeptor-agonisten bei der behandlung von glaukom
|
EP1541151B1
(de)
*
|
2002-08-29 |
2012-02-22 |
Santen Pharmaceutical Co., Ltd. |
MITTEL ZUR BEHANDLUNG VON GLAUKOM MIT EINEM Rho-KINASE-HEMMER UND PROSTAGLANDINEN
|
CN1678302A
(zh)
*
|
2002-08-30 |
2005-10-05 |
爱尔康公司 |
取代的5-苯并二氢吡喃-5-基-乙胺化合物及其在治疗青光眼中的用途
|
KR20050057251A
(ko)
|
2002-09-09 |
2005-06-16 |
산텐 세이야꾸 가부시키가이샤 |
라타노프로스트를 유효 성분으로 하는 투명한 점안액
|
US7074827B2
(en)
*
|
2002-10-24 |
2006-07-11 |
Sucampo Ag (Usa) Inc. |
Method for treating ocular hypertension and glaucoma
|
AU2003275840A1
(en)
*
|
2002-10-25 |
2004-05-13 |
Merck Frosst Canada Ltd |
2-pyrrolidones as EP4 receptor agonists
|
US7196082B2
(en)
|
2002-11-08 |
2007-03-27 |
Merck & Co. Inc. |
Ophthalmic compositions for treating ocular hypertension
|
US7528163B2
(en)
*
|
2002-11-08 |
2009-05-05 |
Merck & Co. Inc. |
Ophthalmic compositions for treating ocular hypertension
|
AU2003286686B2
(en)
*
|
2002-11-12 |
2009-07-16 |
Alcon, Inc. |
Histone deacetylase inhibitors for treating degenerative diseases of the eye
|
US20080004311A1
(en)
*
|
2002-11-12 |
2008-01-03 |
Alcon, Inc. |
Histone deacetylase inhibitors for treating degenerative diseases of the eye
|
ES2444841T3
(es)
|
2002-11-18 |
2014-02-27 |
Santen Pharmaceutical Co., Ltd. |
Remedio para el glaucoma que comprende inhibidor de Rho cinasa y beta-bloqueante
|
US7053085B2
(en)
|
2003-03-26 |
2006-05-30 |
Merck & Co. Inc. |
EP4 receptor agonist, compositions and methods thereof
|
AU2003300915B2
(en)
*
|
2002-12-13 |
2008-08-28 |
Alcon, Inc. |
Novel benzopyran analogs and their use for the treatment of glaucoma
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
AR043161A1
(es)
*
|
2003-02-14 |
2005-07-20 |
Sucampo Pharmaceuticals Inc |
Composicion oftalmica para tratar hipertension ocular y glaucoma
|
CN1816530A
(zh)
*
|
2003-07-01 |
2006-08-09 |
麦克公司 |
用于治疗高眼压症的眼用组合物
|
US20050119262A1
(en)
*
|
2003-08-21 |
2005-06-02 |
Pharmacia Corporation |
Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
|
CA2536281C
(en)
*
|
2003-08-21 |
2012-05-15 |
Sucampo Ag |
Ophthalmic composition comprising a 15-keto-prostaglandin compound
|
CA2537119A1
(en)
*
|
2003-09-02 |
2005-03-10 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
CA2537430A1
(en)
*
|
2003-09-04 |
2005-03-24 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
EP1663987B1
(de)
*
|
2003-09-04 |
2009-03-18 |
Merck & Co., Inc. |
Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
|
US20050058730A1
(en)
*
|
2003-09-15 |
2005-03-17 |
Xushan Wan |
Compositions and methods for preventing or treating eyestrain
|
AU2004285486A1
(en)
*
|
2003-10-22 |
2005-05-12 |
University Of Rochester |
Use of peroxisome proliferator-activated receptor gamma (PPARgamma) and/or retinoic acid receptor (RXR) agonists to inhibit platelet functions
|
JP4762718B2
(ja)
*
|
2003-11-07 |
2011-08-31 |
千寿製薬株式会社 |
プロスタグランジン含有医薬組成物
|
US20090148527A1
(en)
*
|
2007-12-07 |
2009-06-11 |
Robinson Michael R |
Intraocular formulation
|
US20070224278A1
(en)
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
US20050101582A1
(en)
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
US7476687B2
(en)
*
|
2003-11-26 |
2009-01-13 |
Alcon, Inc. |
Substituted furo[2,3-g]indazoles for the treatment of glaucoma
|
US7129257B1
(en)
*
|
2003-12-15 |
2006-10-31 |
Alcon, Inc. |
Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
|
AR046890A1
(es)
*
|
2003-12-15 |
2005-12-28 |
Alcon Inc |
[1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
|
US7338972B1
(en)
|
2003-12-15 |
2008-03-04 |
Alcon, Inc. |
Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
|
BRPI0418245B8
(pt)
|
2004-01-05 |
2021-05-25 |
Nicox Sa |
composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes
|
DE602005011928D1
(de)
|
2004-01-20 |
2009-02-05 |
Allergan Inc |
Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
|
KR20110091600A
(ko)
*
|
2004-04-26 |
2011-08-11 |
알콘, 인코퍼레이티드 |
고안압증과 녹내장의 치료용 스타틴
|
US8512738B2
(en)
|
2004-04-30 |
2013-08-20 |
Allergan, Inc. |
Biodegradable intravitreal tyrosine kinase implants
|
US8147865B2
(en)
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US8455656B2
(en)
|
2004-04-30 |
2013-06-04 |
Allergan, Inc. |
Kinase inhibitors
|
US20050244469A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
US8591885B2
(en)
|
2004-04-30 |
2013-11-26 |
Allergan, Inc. |
Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
|
US20050244463A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
US8425929B2
(en)
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
US8673341B2
(en)
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
US8119154B2
(en)
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
US20050244458A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
AU2005274972A1
(en)
|
2004-07-20 |
2006-02-23 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
US7183310B2
(en)
|
2004-08-10 |
2007-02-27 |
Allergan, Inc. |
Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
SE0402029D0
(sv)
*
|
2004-08-17 |
2004-08-17 |
Synphora Ab |
Prostaglandin a derivatieves for the treatment of psoriasis
|
US9993558B2
(en)
|
2004-10-01 |
2018-06-12 |
Ramscor, Inc. |
Sustained release eye drop formulations
|
US8541413B2
(en)
*
|
2004-10-01 |
2013-09-24 |
Ramscor, Inc. |
Sustained release eye drop formulations
|
WO2006044425A2
(en)
*
|
2004-10-13 |
2006-04-27 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
JP2008515973A
(ja)
*
|
2004-10-13 |
2008-05-15 |
メルク エンド カムパニー インコーポレーテッド |
高眼圧症を治療するための眼科組成物
|
WO2006062839A1
(en)
*
|
2004-12-08 |
2006-06-15 |
Alcon, Inc. |
Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
|
US7851504B2
(en)
|
2005-03-16 |
2010-12-14 |
Allergan, Inc. |
Enhanced bimatoprost ophthalmic solution
|
US9241918B2
(en)
|
2005-03-16 |
2016-01-26 |
Allergan, Inc. |
Enhanced bimatoprost ophthalmic solution
|
KR101396731B1
(ko)
|
2005-03-31 |
2014-05-19 |
산텐 세이야꾸 가부시키가이샤 |
프로스타글란딘 F2a 유도체를 유효 성분으로서 함유하는망막신경세포 보호제
|
CN101160128B
(zh)
|
2005-04-13 |
2010-08-18 |
宇部兴产株式会社 |
含有吲唑衍生物作为有效成分的视网膜神经细胞保护剂
|
US20060293378A1
(en)
*
|
2005-06-28 |
2006-12-28 |
Mcintire Gregory |
Method of lowering intraocular pressure
|
WO2007000641A2
(en)
*
|
2005-06-29 |
2007-01-04 |
Pfizer Inc. |
Prostaglandin derivatives
|
US20090270395A1
(en)
*
|
2005-08-03 |
2009-10-29 |
John Colucci |
EP4 Receptor Agonist, Compositions and Methods Thereof
|
TW200744567A
(en)
*
|
2005-09-23 |
2007-12-16 |
Alcon Inc |
Phenylethylamine analogs and their use for treating glaucoma
|
US7863318B2
(en)
|
2005-11-03 |
2011-01-04 |
Allergan, Inc. |
Prostaglandins and analogues as agents for lowering intraocular pressure
|
CA2644716A1
(en)
*
|
2006-03-13 |
2007-09-27 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
US7666912B2
(en)
|
2006-03-23 |
2010-02-23 |
Massachusetts Eye And Ear Infirmary |
Compositions and methods for reducing body fat
|
WO2007146136A2
(en)
*
|
2006-06-12 |
2007-12-21 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
US8802128B2
(en)
|
2006-06-23 |
2014-08-12 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US7642370B2
(en)
|
2006-08-07 |
2010-01-05 |
Daiichi Fine Chemical Co., Ltd. |
Method for preparing prostaglandin derivative
|
JP5378219B2
(ja)
|
2006-10-02 |
2013-12-25 |
テックフィールズ バイオケム カンパニー リミテッド |
非常に高い皮膚浸透率を有するプロスタグランジン及び関連化合物の正荷電水溶性プロドラッグ
|
WO2008041059A1
(en)
|
2006-10-03 |
2008-04-10 |
Techfields Biochem Co. Ltd |
Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates
|
US8969415B2
(en)
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
US8455513B2
(en)
|
2007-01-10 |
2013-06-04 |
Aerie Pharmaceuticals, Inc. |
6-aminoisoquinoline compounds
|
UY30883A1
(es)
|
2007-01-31 |
2008-05-31 |
Alcon Res |
Tapones punctales y metodos de liberacion de agentes terapeuticos
|
JPWO2008096804A1
(ja)
|
2007-02-07 |
2010-05-27 |
テイカ製薬株式会社 |
ラタノプロスト含有点眼剤
|
US20090018204A1
(en)
*
|
2007-07-13 |
2009-01-15 |
Brinkenhoff Michael C |
Composition and method for enhancing hair growth
|
EP2077104A1
(de)
|
2008-01-02 |
2009-07-08 |
Novagali Pharma SA |
Mizellare Zusammensetzungen mit ophtalmischen Anwendungen
|
US20090170944A1
(en)
*
|
2008-01-02 |
2009-07-02 |
Novagali Pharma Sa |
Ophthalmic micellar compositions with enhanced stability
|
US20090169629A1
(en)
*
|
2008-01-02 |
2009-07-02 |
Novagali Pharma Sa |
Micellar compositions with ophthalmic applications
|
EP2077105A1
(de)
|
2008-01-02 |
2009-07-08 |
Novagali Pharma SA |
Ophthalmische mizellare Zusammensetzung mit erhöhter Stabilität
|
EP2135860A1
(de)
*
|
2008-06-20 |
2009-12-23 |
Sandoz AG |
Verbesserter Herstellungsverfahren für Bimatoprost
|
EP2143712A1
(de)
*
|
2008-07-10 |
2010-01-13 |
Sandoz AG |
Verbessertes Verfahren zur Herstellung von Prostaglandinen und Prostaglandin-Analogen
|
US8450344B2
(en)
|
2008-07-25 |
2013-05-28 |
Aerie Pharmaceuticals, Inc. |
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
|
US8623918B2
(en)
*
|
2008-10-29 |
2014-01-07 |
Novaer Holdings, Inc. |
Amino acid salts of prostaglandins
|
US8722739B2
(en)
|
2008-10-29 |
2014-05-13 |
Novaer Holdings, Inc. |
Amino acid salts of prostaglandins
|
CA2739571A1
(en)
|
2008-10-29 |
2010-08-26 |
Aerie Pharmaceuticals, Inc. |
Amino acid salts of prostaglandins
|
US20100204335A1
(en)
*
|
2008-12-01 |
2010-08-12 |
Allergan, Inc. |
Kit and composition for eyelash growth
|
IT1392492B1
(it)
|
2008-12-24 |
2012-03-09 |
Ind Chimica Srl |
Processo per la purificazione del latanoprost, analogo sintetico della prostaglandina pgf2alfa.
|
US20110293549A1
(en)
|
2009-02-03 |
2011-12-01 |
Athena Cosmetics, Inc. |
Composition, method and kit for enhancing hair
|
WO2010112615A1
(en)
|
2009-04-03 |
2010-10-07 |
Dsm Ip Assets B.V. |
Lysine derivatives functionalised with lipids
|
EP2424842B1
(de)
|
2009-05-01 |
2015-10-28 |
Aerie Pharmaceuticals, Inc. |
Hemmer mit doppelmechanismus zur behandlung von erkrankungen
|
EP2478906A4
(de)
|
2009-09-17 |
2013-02-20 |
Senju Pharma Co |
Latanoprosthaltige wässrige augentropfen und verfahren zur adsorption von latanoprost an einem kunstharz
|
DK2498783T3
(en)
*
|
2009-11-09 |
2018-12-10 |
Allergan Inc |
COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
|
US9149484B2
(en)
|
2009-11-09 |
2015-10-06 |
Allergan, Inc. |
Compositions and methods for stimulating hair growth
|
US9522153B2
(en)
|
2009-12-22 |
2016-12-20 |
Allergan, Inc. |
Compositions and methods for lowering intraocular pressure
|
JP2013516495A
(ja)
*
|
2010-01-11 |
2013-05-13 |
イノテック ファーマシューティカルズ コーポレイション |
眼圧を低下させる組合せ、キット、および方法
|
WO2011095990A2
(en)
|
2010-02-03 |
2011-08-11 |
Fdc Limited |
Process for the purification of prostaglandins and analogues thereof
|
SG184221A1
(en)
|
2010-03-26 |
2012-10-30 |
Inotek Pharmaceuticals Corp |
Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
|
CN103052406A
(zh)
*
|
2010-07-19 |
2013-04-17 |
印斯拜尔药品股份有限公司 |
双官能rho激酶抑制剂化合物、组合物及应用
|
SI3431074T1
(sl)
|
2010-07-29 |
2022-07-29 |
Allergan, Inc. |
Raztopine bimatoprosta in timolola brez konzervansov
|
US9061034B2
(en)
|
2010-07-29 |
2015-06-23 |
Allergan, Inc. |
Preservative free bimatoprost and timolol solutions
|
EP2600825B1
(de)
|
2010-08-02 |
2018-12-12 |
Ac Patent Holding Inc. |
Verfahren zum locekn von Haar
|
US20140079686A1
(en)
|
2010-12-06 |
2014-03-20 |
Shikha P. Barman |
Methods For Treating Baldness And Promoting Hair Growth
|
CA2824317C
(en)
|
2011-01-19 |
2014-12-16 |
Terakine Therapeutics, Inc. |
Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
|
US8859616B2
(en)
|
2011-01-21 |
2014-10-14 |
Allergan, Inc. |
Compounds and methods for enhancing hair growth
|
TW201906614A
(zh)
|
2011-02-04 |
2019-02-16 |
日商興和股份有限公司 |
青光眼或高眼壓症之預防或治療用之點眼藥
|
EP2495235B1
(de)
|
2011-03-04 |
2015-08-05 |
Newchem S.p.A. |
Herstellungsverfahren zur Synthese von Prostaglandinen und Zwischenprodukte davon
|
CN102690219A
(zh)
*
|
2011-03-24 |
2012-09-26 |
天津信汇制药股份有限公司 |
纯化贝美前列素的方法
|
EP2701680B1
(de)
|
2011-04-29 |
2018-10-31 |
Allergan, Inc. |
Latanoprost-implantat mit verzögerter freisetzung
|
KR102135550B1
(ko)
*
|
2011-06-02 |
2020-07-21 |
키노인 제트알티. |
프로스타글란딘 아미드의 신규한 제조 방법
|
US8426471B1
(en)
|
2011-12-19 |
2013-04-23 |
Topokine Therapeutics, Inc. |
Methods and compositions for reducing body fat and adipocytes
|
PT2807178T
(pt)
|
2012-01-26 |
2017-08-08 |
Inotek Pharmaceuticals Corp |
Polimorfos anidros de nitrato de (2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-dihidroxitetrahidrofuran-2-il)}metilo e seus processos de preparação
|
EP2822927A1
(de)
*
|
2012-03-09 |
2015-01-14 |
Instytut Farmaceutyczny |
Verfahren zur herstellung von prostaglandin-f2-alpha-analogen
|
CA2869676C
(en)
|
2012-11-21 |
2015-06-23 |
Topokine Therapeutics, Inc. |
Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat
|
US9120738B2
(en)
|
2012-12-28 |
2015-09-01 |
Allergan, Inc. |
Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof
|
CN104994815B
(zh)
|
2013-02-15 |
2018-07-31 |
阿勒根公司 |
持续药物递送植入物
|
WO2014144781A1
(en)
|
2013-03-15 |
2014-09-18 |
Aerie Pharmaceuticals, Inc. |
Combination therapy
|
CN105188714A
(zh)
|
2013-03-15 |
2015-12-23 |
伊诺泰克制药公司 |
眼用配制品
|
NO2753788T3
(de)
|
2013-05-10 |
2018-06-16 |
|
|
US9820993B2
(en)
|
2013-05-15 |
2017-11-21 |
Topokine Therapeutics, Inc. |
Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
|
ITMI20132193A1
(it)
*
|
2013-12-23 |
2015-06-24 |
Ind Chimica Srl |
Processo microbiologico per la preparazione di intermedi utili nella sintesi di prostaglandine
|
HU231214B1
(hu)
*
|
2014-03-13 |
2021-11-29 |
CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. |
Új eljárás nagytisztaságú prosztaglandinok előállítására
|
US10188661B2
(en)
|
2014-06-27 |
2019-01-29 |
Topokine Therapeutics, Inc. |
Topical dosage regimen
|
EA034839B1
(ru)
|
2014-10-20 |
2020-03-26 |
Сентисс Фарма Прайвет Лимитед |
Офтальмологический раствор
|
KR102511830B1
(ko)
|
2014-11-25 |
2023-03-17 |
엑시모어 엘티디. |
단일 및 다수 생체활성제를 전달하기 위한 조성물 및 방법
|
CA2999988A1
(en)
|
2015-09-27 |
2017-03-30 |
Follica, Inc. |
Needling device and drug applicator
|
US9643927B1
(en)
|
2015-11-17 |
2017-05-09 |
Aerie Pharmaceuticals, Inc. |
Process for the preparation of kinase inhibitors and intermediates thereof
|
KR102568082B1
(ko)
|
2016-08-31 |
2023-08-17 |
에어리 파마슈티컬즈, 인코포레이티드 |
안과용 조성물
|
WO2018183911A1
(en)
|
2017-03-31 |
2018-10-04 |
Aerie Pharmaceuticals, Inc. |
Aryl cyclopropyl-amino-isoquinolinyl amide compounds
|
AU2019337703B2
(en)
|
2018-09-14 |
2023-02-02 |
Aerie Pharmaceuticals, Inc. |
Aryl cyclopropyl-amino-isoquinolinyl amide compounds
|
CN112142703A
(zh)
*
|
2020-09-30 |
2020-12-29 |
东北制药集团股份有限公司 |
一种卡前列素氨丁三醇相关杂质左旋丁基15-酮及其制备方法
|